Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

NCT01009593 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT01009593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01009593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2010
Completion date
July 31, 2012
Enrollment
1,035 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, carcinoma, carcinoma, hepatocellular, digestive system diseases, digestive system neoplasms, hepatocellular carcinoma non-resectable, hepatocellular carcinoma recurrent, liver diseases, liver neoplasms, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, glandular and epithelial